Valius Sciences

Valius Sciences

Multi-omic cancer diagnostics with data platform

Overview

Valius Sciences develops precision oncology diagnostics that build detailed molecular profiles of tumors across DNA, RNA, and proteins to guide treatment choices. Its test combines multi-omic data and extensive gene expression analysis to identify actionable targets and cancer drivers that may be missed by standard tests. Rather than static PDFs, it offers a partnership model with an AI-queryable platform that stores all patient data and enables ongoing analysis and collaboration with Valius's scientific team. The goal is to help patients and clinicians prioritize effective therapies and plan for recurrence or progression through continuous, data-driven insights.

Launched Recently

About Valius Sciences

Simplify's Rating
Why Valius Sciences is rated
C+
Rated B on Competitive Edge
Rated C on Growth Potential
Rated C on Differentiation

Industries

Data & Analytics

AI & Machine Learning

Biotechnology

Healthcare

Company Size

11-50

Company Stage

Seed

Total Funding

$10M

Headquarters

San Francisco, California

Founded

2025

Get referred to Valius Sciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Valius raised $13.5 million on April 9, 2026, from 8VC and Basis Set.
  • The company now advertises active support for trial matching and single-patient INDs.
  • Valius says it is expanding clinical single-cell gene-expression analysis and its scientist team.

What critics are saying

  • Direct-pay pricing of $50,000-$90,000 kills routine adoption without reimbursement.
  • Tempus, Guardant Health, and Foundation Medicine already own oncologist workflows.
  • If payers or tumor boards reject maximalist reports, Valius loses referrals quickly.

What makes Valius Sciences unique

  • Valius sells DNA-RNA-protein tumor profiling, not single-layer sequencing.
  • It offers direct-pay, patient-facing interpretation plus ongoing scientific collaboration.
  • Its platform supports clinical trial matching, single-patient INDs, and recurrence monitoring.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$10M

Above

Industry Average

Funded Over

1 Rounds

Seed funding is usually the first official round after pre-seed, when a startup has a prototype or concept. It’s typically used to develop the product, test the market, and start building the team. Investors here are often angel investors or early-stage venture capitalists.
Seed Funding Comparison
Above Average

Industry standards

$3.3M
$2M
Netflix
$2.3M
Instacart
$3M
Robinhood
$10M
Valius Sciences

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Company Equity

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Valius Sciences
May 2nd, 2026
Valius Sciences – Valius raises $10M to build the future of cancer diagnostics

We're bringing maximalist diagnostics to more patients.

Legal Desire
Apr 27th, 2026
Valius Sciences raises $10M to develop cancer diagnostics

Valius Sciences, a San Francisco-based healthcare diagnostics company focused on cancer treatment, has raised more than $10 million in a Series Seed financing round. The round was led by 8VC and Basis Set Ventures. Sidley represented the company in the transaction.

Recently Posted Jobs

Sign up to get curated job recommendations

Valius Sciences is Hiring for 5 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →